HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate and ADA team up

This article was originally published in The Rose Sheet

Executive Summary

Colgate-Palmolive has signed on to be a national strategic partner of the American Diabetes Association, backing ADA's oral-care activities "which will seek to further the understanding of the connection between oral health and diabetes," according to April 2 release. ADA and Colgate will collaborate on educating patients, healthcare professionals and the public about the "importance of good oral care for people with diabetes" and for those at risk of developing the disease. Diabetes patients are estimated to be 2 to 5 times more likely to develop gum disease than people without diabetes, according to the association. Colgate additionally will support ADA's "Ask the Dentist" online chat series and the oral hygiene section of 1www.diabetes.org...

You may also be interested in...



Sanofi Skates To Where The Puck Is With Immunology

The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.

Pipeline Watch: Five Approvals And 23 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel